Amylyx Pharmaceuticals earnings were -$218.9M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest AMLX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$35.9M, down 4.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AMLX reported annual earnings of -$301.7M, with -712.4% growth. The next AMLX earnings date is Jun 6, 2025.
Amylyx Pharmaceuticals Earnings Reports & History FAQ
What were Amylyx Pharmaceuticals's earnings last quarter?
On AMLX's earnings call on Invalid Date, Amylyx Pharmaceuticals (NASDAQ: AMLX) reported Q1 2025 earnings per share (EPS) of -$0.42, up 76% year over year. Total AMLX earnings for the quarter were -$35.91 million. In the same quarter last year, Amylyx Pharmaceuticals's earnings per share (EPS) was -$1.75.
The next AMLX earnings date is Invalid Date. Add AMLX to your watchlist to be reminded of Amylyx Pharmaceuticals's next earnings date.
Is Amylyx Pharmaceuticals profitable or losing money?
As of the last Amylyx Pharmaceuticals earnings report, Amylyx Pharmaceuticals is currently losing money. Amylyx Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$218.86 million, a 207.84% increase year over year.
What was AMLX's earnings growth in the past year?
As of Amylyx Pharmaceuticals's earnings date in Invalid Date, Amylyx Pharmaceuticals's earnings has grown year over year. AMLX earnings in the past year totalled -$218.86 million.
What are Amylyx Pharmaceuticals's earnings expectations?
The current EPS estimate for Amylyx Pharmaceuticals's earnings report in Invalid Date is -$0.50.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.